ZA200606804B - Pharmaceutical composition for treatment of immunological disorders - Google Patents

Pharmaceutical composition for treatment of immunological disorders

Info

Publication number
ZA200606804B
ZA200606804B ZA200606804A ZA200606804A ZA200606804B ZA 200606804 B ZA200606804 B ZA 200606804B ZA 200606804 A ZA200606804 A ZA 200606804A ZA 200606804 A ZA200606804 A ZA 200606804A ZA 200606804 B ZA200606804 B ZA 200606804B
Authority
ZA
South Africa
Prior art keywords
treatment
pharmaceutical composition
immunological disorders
immunological
disorders
Prior art date
Application number
ZA200606804A
Other languages
English (en)
Inventor
Chung Yong-Hoon
Cho Hoon-Sik
Park Hong-Gyu
Yi Ki-Wan
Original Assignee
Medexgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medexgen Inc filed Critical Medexgen Inc
Publication of ZA200606804B publication Critical patent/ZA200606804B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A47—FURNITURE; DOMESTIC ARTICLES OR APPLIANCES; COFFEE MILLS; SPICE MILLS; SUCTION CLEANERS IN GENERAL
    • A47J—KITCHEN EQUIPMENT; COFFEE MILLS; SPICE MILLS; APPARATUS FOR MAKING BEVERAGES
    • A47J37/00—Baking; Roasting; Grilling; Frying
    • A47J37/04—Roasting apparatus with movably-mounted food supports or with movable heating implements; Spits
    • A47J37/049—Details of the food supports not specially adapted to one of the preceding types of food supports
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A22—BUTCHERING; MEAT TREATMENT; PROCESSING POULTRY OR FISH
    • A22C—PROCESSING MEAT, POULTRY, OR FISH
    • A22C17/00—Other devices for processing meat or bones
    • A22C17/006—Putting meat on skewers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Food Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
ZA200606804A 2004-02-18 2006-08-16 Pharmaceutical composition for treatment of immunological disorders ZA200606804B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020040010835A KR20050082389A (ko) 2004-02-18 2004-02-18 직렬 연쇄체를 갖는 면역접합체를 포함하는 장기이식합병증 치료용 약제학적 조성물

Publications (1)

Publication Number Publication Date
ZA200606804B true ZA200606804B (en) 2008-04-30

Family

ID=34858737

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200606804A ZA200606804B (en) 2004-02-18 2006-08-16 Pharmaceutical composition for treatment of immunological disorders

Country Status (11)

Country Link
US (1) US20070110746A1 (fr)
EP (1) EP1615664A4 (fr)
JP (1) JP2007523158A (fr)
KR (2) KR20050082389A (fr)
CN (1) CN1942206A (fr)
AU (1) AU2005203104B2 (fr)
BR (1) BRPI0507216A (fr)
CA (1) CA2556739A1 (fr)
RU (1) RU2342950C2 (fr)
WO (1) WO2005077415A1 (fr)
ZA (1) ZA200606804B (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006033702A2 (fr) 2004-07-26 2006-03-30 Biogen Idec Ma Inc. Anticorps anti-cd154
KR101301649B1 (ko) 2006-11-10 2013-08-30 삼성전자주식회사 기록/재생 방법, 기록/재생 장치 및 정보 저장 매체
KR100963030B1 (ko) * 2008-03-31 2010-06-10 한화케미칼 주식회사 이식 면역 반응을 억제할 수 있는 ｃｄ７０ 발현신경줄기세포 및 그의 이용
ES2588194T3 (es) * 2008-04-11 2016-10-31 Seattle Genetics, Inc. Detección y tratamiento de cáncer pancreático, de ovario y otros cánceres
EP2193790A1 (fr) 2008-12-04 2010-06-09 Klinikum der Universität Regensburg Inhibiteurs IL-3 à utiliser pour le traitement de l'arthrite rhumatoïde à un stade précoce
CN108997498A (zh) 2008-12-09 2018-12-14 霍夫曼-拉罗奇有限公司 抗-pd-l1抗体及它们用于增强t细胞功能的用途
BR112012013330A2 (pt) 2009-12-02 2017-03-28 Acceleron Pharma Inc composições e métodos para aumentar meia vida do soro de proteínas de fusão fc
EP2718328A4 (fr) * 2011-06-08 2014-12-24 Acceleron Pharma Inc Compositions et procédés pour augmenter la demi-vie sérique
CN103045646B (zh) * 2012-12-27 2015-02-25 中国人民解放军军事医学科学院基础医学研究所 共表达两个独立的抗关节炎分子TNFR-Fc和CTLA4-FasL的重组腺相关病毒载体及其构建方法与应用
CN104231086B (zh) * 2013-08-27 2019-12-13 北京韩美药品有限公司 双功能融合蛋白及其制备方法和用途
KR101640582B1 (ko) * 2014-05-09 2016-07-18 고려대학교 산학협력단 Ｌａｇ－3의 세포질 도메인을 포함하는 면역세포 표면에의 단백질 발현용 조성물 및 그의 이용
TWI693232B (zh) 2014-06-26 2020-05-11 美商宏觀基因股份有限公司 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
FR3031112B1 (fr) * 2014-12-24 2018-05-25 Eyevensys Construction d'adn pour le traitement de pathologies oculaires
TWI773646B (zh) 2015-06-08 2022-08-11 美商宏觀基因股份有限公司 結合lag-3的分子和其使用方法
IL297090A (en) 2015-07-30 2022-12-01 Macrogenics Inc Molecules that bind pd-1 and methods of using them
TWI758267B (zh) 2015-12-14 2022-03-21 美商宏觀基因股份有限公司 對於pd-1和ctla-4具有免疫反應性的雙特異性分子及其使用方法
TR201807610T1 (tr) * 2015-12-21 2018-06-21 Brainon Inc Hafizanin, öğrenme beceri̇si̇ni̇n ve bi̇li̇şsel beceri̇ni̇n geli̇şti̇ri̇lmesi̇ i̇çi̇n kompozi̇syon
PT3565828T (pt) 2017-01-05 2022-02-08 Kahr Medical Ltd Proteína de fusão sirp1 alfa-41bbl e seus métodos de utilização
US11566060B2 (en) 2017-01-05 2023-01-31 Kahr Medical Ltd. PD1-CD70 fusion protein and methods of use thereof
US11299530B2 (en) 2017-01-05 2022-04-12 Kahr Medical Ltd. SIRP alpha-CD70 fusion protein and methods of use thereof
CA3047707A1 (fr) 2017-01-05 2018-07-12 Kahr Medical Ltd. Proteine de fusion pd1-41bbl et ses methodes d'utilisation
WO2018152687A1 (fr) * 2017-02-22 2018-08-30 I-Mab Anticorps dirigés contre le gène-3 d'activation des lymphocytes (lag-3) et leurs utilisations
SG11201909154SA (en) 2017-04-05 2019-10-30 Hoffmann La Roche Bispecific antibodies specifically binding to pd1 and lag3
US20210214417A1 (en) 2018-07-11 2021-07-15 Kahr Medical Ltd. SIRPalpha-4-1BBL VARIANT FUSION PROTEIN AND METHODS OF USE THEREOF

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4143214A1 (de) * 1991-07-25 1993-01-28 Boehringer Mannheim Gmbh Synergistisch wirkende antikoerperzusammensetzung
ATE210454T1 (de) * 1991-10-07 2001-12-15 Biogen Inc Verfahren zur verbesserung der toleranz für allotransplantaten und xenotransplantaten durch verabreichung eines lfa-3- oder cd2- bindungsproteins
JPH09510952A (ja) * 1993-10-06 1997-11-04 ザ ケネディー インスティチュート オブ リューマトロジー 自己免疫疾患および炎症性疾患の治療
AU2701895A (en) * 1994-06-07 1996-01-05 Regents Of The University Of Minnesota Methods for inhibiting antigen specific t cell responses
IL130168A (en) * 1996-11-29 2006-09-05 Serono Lab Genetically engineered cells containing LAG-3-expressing DNA and their use
EP0893507A1 (fr) * 1997-07-25 1999-01-27 Institut Gustave Roussy Utilisation de ligands de MHC classe II (CD4 et LAG-3) comme adjuvants pour la vaccination de LAG-3 dans le traitement du cancer
US6797263B2 (en) * 2000-05-12 2004-09-28 Beth Israel Deaconess Medical Center, Inc. Compositions and methods for achieving immune suppression
US7094874B2 (en) * 2000-05-26 2006-08-22 Bristol-Myers Squibb Co. Soluble CTLA4 mutant molecules
EP1289554A4 (fr) * 2000-06-02 2004-05-26 Univ Minnesota Procede immunotherapeutique permettant de prevenir le rejet de cellules insulaires
KR100453877B1 (ko) * 2001-07-26 2004-10-20 메덱스젠 주식회사 연쇄체화에 의한 면역 글로블린 융합 단백질의 제조 방법 및 이 방법에 의해 제조된 ＴＮＦＲ/Ｆｃ 융합 단백질, 상기 단백질을 코딩하는 ＤＮＡ, 상기 ＤＮＡ를 포함하는벡터, 및 상기 벡터에 의한 형질전환체

Also Published As

Publication number Publication date
EP1615664A4 (fr) 2006-12-27
RU2006133911A (ru) 2008-03-27
WO2005077415A1 (fr) 2005-08-25
AU2005203104A9 (en) 2005-09-01
AU2005203104B2 (en) 2006-11-16
US20070110746A1 (en) 2007-05-17
RU2342950C2 (ru) 2009-01-10
CN1942206A (zh) 2007-04-04
JP2007523158A (ja) 2007-08-16
AU2005203104A1 (en) 2005-09-01
CA2556739A1 (fr) 2005-08-25
KR100658050B1 (ko) 2006-12-15
EP1615664A1 (fr) 2006-01-18
KR20060002740A (ko) 2006-01-09
KR20050082389A (ko) 2005-08-23
BRPI0507216A (pt) 2007-06-19

Similar Documents

Publication Publication Date Title
ZA200606804B (en) Pharmaceutical composition for treatment of immunological disorders
IL178730A0 (en) New pharmaceutical compositions for the treatment of sexual disorders ii
TWI369987B (en) New pharmaceutical compositions for the treatment of hyper-proliferative disorders
EP1833467A4 (fr) Compositions pharmaceutiques destinees a des troubles du sommeil
ZA200607433B (en) Methods and compositions for the treatment of gastroin-testinal disorders
GB0522311D0 (en) Pharmaceutical compositions for the treatment of pain
IL191283A (en) Compositions for treating eye irregularities
IL177772A0 (en) Methods and compositions for the treatment of gastrointestinal disorders
IL189622A0 (en) Pharmaceutical compositions for the treatment of inner ear disorders
EP2107909A4 (fr) Composes et compositions pharmaceutiques destines au traitement des troubles hepatiques
IL179674A0 (en) Chemical compounds and pharmaceutical compositions containing them for the treatment of inflammatory disorders
IL178775A0 (en) Pharmaceutical compositions for acute glucocorticoid therapy
IL179508A0 (en) 2-substituted-4- heteroaryl-pyrimidines useful for the treatment of proliferative disorders
ZA200801667B (en) Novel pharmaceutical combinations for the treatment of respiratory disorders
IL192415A0 (en) Pharmaceutical composition for the treatment of nail diseases
IL179337A0 (en) Pharmaceutical compositions for the treatment of pruritus
HK1111599A1 (en) Pharmaceutical compositions for the treatment of cellulite
IL181332A (en) A long-term treatment of human gastrointestinal disorders containing prostaglandin compound
HU0500145D0 (en) Composition for the treatment of oral diseases
ZA200609685B (en) Pharmaceutical compositions for acute glucocorticoid therapy
ZA200607463B (en) New pharmaceutical compositions for the treatment of sexual disorders II
TWI365070B (en) Pharmaceutical compositions for prevention or treatment of disorders of lipid metabolism
TWI350171B (en) Pharmaceutical compositions for treatment of cardio-cerebral-vascular diseases
ZA200805859B (en) Methods and compositions for the treatment of gastriontestinal disorders
ZA200704859B (en) Pharmaceutical compositions for the treatment of cellulite